Preclinical evaluation of 99mTc(CO) 3-aspartic-N- monoacetic acid, a renal radiotracer with pharmacokinetic properties comparable to 131I-o-iodohippurate

Journal of Nuclear Medicine

Volumn 53, Issue 8, 2012, Pages 1277-1283

  Lipowska, Malgorzata ^a   Klenc, Jeffrey ^a   Marzilli, Luigi G ^b   Taylor, Andrew T ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

131I ortho iodohippurate; 99mTc; 99mTc(CO) 3(ASMA); Kidney; Renal radiopharmaceuticals; Tricarbonyl

Indexed keywords

ASPARTIC N MONOACETIC ACID TC 99M; CYSTEINE; HISTIDINE; IODOHIPPURATE SODIUM I 123; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; IODOHIPPURIC ACID; LIGAND; RADIOACTIVE IODINE; TECHNETIUM 99M TRICARBONYL ASPARTIC N MONOACETIC ACID; TECHNETIUM 99M TRICARBONYL ASPARTIC-N-MONOACETIC ACID; TECHNETIUM COMPLEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PURITY; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; KIDNEY CLEARANCE; NONHUMAN; PRIORITY JOURNAL; RAT; URINALYSIS; VASCULAR PEDICLE; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; ISOMERISM; KIDNEY; MALE; METABOLISM; SCINTISCANNING; SPRAGUE DAWLEY RAT;

ANIMALS; IODINE RADIOISOTOPES; IODOHIPPURIC ACID; ISOMERISM; ISOTOPE LABELING; KIDNEY; LIGANDS; MALE; ORGANOTECHNETIUM COMPOUNDS; RADIOACTIVE TRACERS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84864765290     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.102236     Document Type: Article

References (40)

1. Coresh J, Selvin E, Stevens L, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038-2047. (Pubitemid 350074801)
2. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a Statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-2169. (Pubitemid 37337595)
3. Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology. 2003;14:479-487. (Pubitemid 40417067)
4. Anderson S, Halter JB, Hazzard WR, et al. Prediction, progression, and outcomes of chronic kidney disease in older adults. J Am Soc Nephrol. 2009;20:1199-1209.
5. Chronic kidney disease. HealthyPeople.gov Web site. Available at: http://www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid56. Updated May 1, 2012. Accessed June 5, 2012.
6. 2011 annual data report. United States Renal Data System Web site. Available at: http://www.usrds.org/adr.htm Accessed June 5, 2012.
7. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-147.
8. Blaufox MD, Potchen EJ, Merrill JP. Measurement of effective renal plasma flow in man by external counting methods. J Nucl Med. 1967;8:77-85.
9. 131I-ortho-iodohippurate absorbed kidney dose: a literature review. Med Phys. 1980;7:249-250.
10. Technical report series no. 466: Technetium-99m radiopharmaceuticals - manufacture of kits. IAEA.org Web site. Available at: http://www-pub.iaea.org/ mtcd/publications/pdf/trs466-web.pdf. Published August 2008. Accessed June 5, 2012.
11. - in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc. 1998;120:7987-7988.
12. Klingensmith WC III, Fritzberg AR, Spitzer VM, et al. Clinical evaluation of Tc-99m N,N′-bis(mercaptoacetyl)-2,3-diaminopropanoate as a replacement for I-131 hippurate. J Nucl Med. 1984;25:42-48. (Pubitemid 14179808)
13. Taylor A, Eshima D, Fritzberg AR, Christian PE, Kasina S. Comparison of iodine-131 OIH and technetium-99m MAG3 renal imaging in volunteers. J Nucl Med. 1986;27:795-803. (Pubitemid 17022667)
14. Jafri RA, Britton K, Nimmon C, et al. Technetium-99m-MAG3, a comparison with iodine-123 and iodine-131-orthoiodohippurate, in patients with renal disorders. J Nucl Med. 1988;29:147-158. (Pubitemid 18056724)
15. Van Nerom CG, De Bormans GM, De Roo MJ, Vernrugen AM. First experience in healthy volunteers with technetium-99m L,L-ethylenedicysteine, a new renal imaging agent. Eur J Nucl Med. 1993;20:738-746. (Pubitemid 23315287)
16. O'Malley JP, Ziessman HA, Chantarapitak N. Tc-99m MAG3 as an alternative to Tc-99m DTPA and I-131 Hippuran for renal transplant evaluation. Clin Nucl Med. 1993;18:22-29. (Pubitemid 23061744)
17. Kabasakal L, Turoglu T, Onsel C, et al. Clinical comparison of technetium-99m-EC, technetium-99m-MAG3 and iodine-131-OIH in renal disorders. J Nucl Med. 1995;36:224-228.
18. Taylor A, Hansen L, Eshima D, et al. Comparison of technetium-99m-LL-EC isomers in rats and humans. J Nucl Med. 1997;38:821-826.
19. 99mTc-EC. J Nucl Med. 2004;45:885-891.
20. 3(LAN), as a new renal radiopharmaceutical in humans. J Nucl Med. 2006;47:1032-1040.
21. 131I-OIH in healthy volunteers. J Nucl Med. 2010;51:391-396.
22. 99mTc renal tubular function agent. Semin Nucl Med. 1992;22:61-73.
23. 99mTc-MAG3 renography: normal values for MAG3 clearance and curve parameters, excretory parameters and residual urine volume. AJR. 2006;187:W610-W617.
24. 131I-OIH. J Nucl Med. 2009;50:454-460.
25. Maher FT, Tauxe WN. Renal clearance in man of pharmaceuticals containing radioactive iodine. JAMA. 1969;207:97-104.
26. Maderová J, Pavelicík F, Marek J. N-(carboxymethyl)aspartic acid. Acta Crystallogr. 2002;E58:o469-o470.
27. Snyder RV, Angelici RJ. Stereoselectivity of N-carboxymethyl-amino acid complexes of copper(II) toward optically active amino acids. J Inorg Nucl Chem. 1973;35:523-535.
28. 3 analogues. Nucl Med Biol. 2007;34:709-716.
29. Müller-Suur R, Müller-Suur C. Renal and extrarenal handling of a new imaging compound (99m-Tc-MAG3) in the rat. Eur J Nucl Med. 1986;12:438-442. (Pubitemid 17037567)
30. Taylor A, Eshima D. Effects of altered physiological states on clearance and biodistribution of technetium-99m MAG3, iodine-131 OIH, and iodine-125 iothalamate. J Nucl Med. 1988;29:669-675.
31. + (M = Re, Tc) directed towards radiopharmaceutical application. Coord Chem Rev. 1999;190-192:901-919.
32. Schibli R, Schubiger AP. Current use and future potential of organometallic radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2002;29:1529-1542. (Pubitemid 35232058)
33. 99mTc: a reflection on technetium core structures and a strategy for new chelate design. Nucl Med Biol. 2005;32:1-20.
34. + and recognized by the L-type amino acid transporter LAT1. J Am Chem Soc. 2006;128:15996-15997.
35. Bartholomä M, Valliant J, Maresca K, Babich J, Zubieta J. Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals. Chem Commun (Camb). 2009;493-512.
36. 99mTc radiopharmaceuticals: dependence on aqueous solution reaction conditions. Inorg Chem. 2010;49:3141-3151.
37. 3 thioether-carboxylate complexes on renal tubular transport [abstract]. J Labelled Comp Radiopharm. 2009;52 (suppl):S473.
38. Nosco DL, Beaty-Nosco JA. Chemistry of technetium radiopharmaceuticals 1: Chemistry behind the development of technetium-99m compounds to determine kidney function. Coord Chem. 1999;184:91-123.
39. Rosen JM. Gallbladder uptake simulating hydronephrosis on Tc-99m MAG3 scintigraphy. Clin Nucl Med. 1993;18:713-714. (Pubitemid 23229611)
40. Shattuck LA, Eshima D, Taylor A, et al. Evaluation of the hepatobiliary excretion of Tc-99m MAG3 and reconstitution factors affecting the radiochemical purity. J Nucl Med. 1994;35:349-355. (Pubitemid 24048326)